Renaissance Capital logo

PTGX News

US IPO Weekly Recap: Medpace leads week's three IPOs

MEDP

This week’s three IPOs raised a combined $263 million. Continuing a streak of outperformance from larger IPOs, contract research organization Medpace led with a 21% gain, while Protagonist Therapeutics was the latest biotech IPO to break issue. ...read more

Protagonist Therapeutics prices upsized IPO at $12, midpoint of the range

Protagonist Therapeutics logo

Protagonist Therapeutics, which is developing peptide-based oral drugs for inflammatory bowel disease, raised $90 million by offering 7.5 million shares at $12, within the range of $11 to $13. The company had originally planned to raise $70 million by offering 5...read more

US IPO Week Ahead: Medpace and three others are on pace for IPOs

MEDP

Four companies are set to raise a combined $270 million in the week ahead. Most notable deal Medpace, a contract research organization focused on biotechs, is joined by two potential customers: Protagonist Therapeutics and Motif Bio. Thanks to insider support,...read more

Protagonist Therapeutics, a GI biotech, sets terms for $70 million IPO

Protagonist Therapeutics logo

Protagonist Therapeutics, which is developing peptide-based oral drugs for gastrointestinal diseases, announced terms for its IPO on Monday. The Milpitas, CA-based company plans to raise $70 million by offering 5.8 million shares at a price range of $11 to...read more